Industrial Biotechnology Corporation has announced the expansion of their License Agreement with Isis Innovation Limited, the technology transfer company of
Immtech Pharmaceuticals has announced that The United States Patent and Trademark Office issued a patent related to the manufacturing of Immtech's drug candidate compounds. Immtech has an
Synergetics has announced that it has received an additional patent covering its bipolar technology through the issuance of U.S. patent number 7,041,096. This patent will provide protect
Mylan Laboratories has announced that U.S. Patent No. 7,070,808 was issued to its subsidiary, Mylan Technologies Inc. (MTI), on July 4, 2006. The '808 Patent contains one or more claims which cov
The Munich-based drug discovery and development company 4SC AG has been informed by the US Patent and Trademark Office (PTO) that the office has granted the patent with the US patent number 7,071,355.
Respironics, Inc. has announced that it has decided to expand its relationship with Masimo and to adopt Masimo's pulse oximetry solution for situa
Pfizer Inc said today that a panel of the Court of Appeals for the Federal Circuit has upheld the exclusivity of the main patent covering atorvastatin, the active ingredient in Lipitor, maintaining pat
SRU Biosystems, Inc. announced today that in connection with the patent litigation brought by Corning Incorporated and Artificial Sensing Instruments ASI AG, the United States District Court for
Novo Nordisk has announced that the company filed a lawsuit against Pfizer claiming that Pfizer's product Exubera infringes patents owned by Novo Nordisk. The patents cover inhaled insulin treatme
Ranbaxy announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) handed down a judgment in its case challenging two key atorvastatin patents held by Pfizer. Atorvastatin is
Fibroblasts are relatively generic, easily maintained, human cells that form connective tissues throughout the body. By knowing the specific sequences of DNA that control the nearly 8,000 active genes in fibroblasts, scientists can tease apart the biochemical regulation system these cells use to turn genes on and off during normal growth.
The so-called "promoter map" will not only provide new insight into how genes are controlled in fibroblasts, but will also serve as a framework for analysis of genetic control in other human cell types, tissues and perhaps organs.
The project, detailed in a June 29 electronic edition of the journal, Nature, is a collaboration headed by Bing Ren at University of California, San Diego, working with scientists at University of California, Los Angeles (UCLA) and the company Nimblegen, Inc., in Madison, Wisc.
Understanding the on-off control mechanisms will further understanding of how a cell is programmed to perform specialized functions. Nearly all cells in the human body have the same genetic information. But they don't all express it at the same time. Cells in the heart, for example, express different information than do cells of the liver or brain. Controlled gene activity at certain times determines what function the cell will have in the body.
To accomplish the genome-wide promoter survey, Bing Ren and his co-worker, Tae Hoon Kim, conceived and designed a novel experimental procedure based on cutting-edge microarray technology. UCLA's Yingnian Wu and Ming Zheng developed sophisticated computer algorithms to process the massive amount of data collected from the experiments.
The researchers report that multiple promoters often control a single gene in parallel, adding another layer to an already complex genetic regulation mechanism. They also discovered promoters in front of DNA sequences not previously recognized as genes. The significance of that finding will be determined in future studies.
http://www.nsf.gov/